|
Oct 9
|
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ...
|
|
Sep 25
|
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
|
|
Jun 19
|
Are Medical Stocks Lagging DURECT (DRRX) This Year?
|
|
May 21
|
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
|
|
May 14
|
Q1 2024 DURECT Corp Earnings Call
|
|
May 14
|
Durect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...
|
|
May 13
|
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 13
|
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
|
|
May 7
|
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
|
|
Apr 30
|
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
|
|
Apr 1
|
DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript
|
|
Mar 27
|
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
|
|
Mar 27
|
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 20
|
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
|
|
Mar 4
|
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
|
|
Nov 14
|
Q3 2023 DURECT Corp Earnings Call
|
|
Nov 7
|
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
|
|
Aug 10
|
Q2 2023 DURECT Corp Earnings Call
|
|
Aug 9
|
Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 9
|
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
|